Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
EDAP's Cash to Debt is ranked higher than
91% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. EDAP: No Debt )
EDAP' s 10-Year Cash to Debt Range
Min: 0.37   Max: No Debt
Current: No Debt

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -7.79
EDAP's Operating margin (%) is ranked higher than
54% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. EDAP: -7.79 )
EDAP' s 10-Year Operating margin (%) Range
Min: -43.96   Max: -2.5
Current: -7.79

-43.96
-2.5
Net-margin (%) -28.68
EDAP's Net-margin (%) is ranked lower than
51% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. EDAP: -28.68 )
EDAP' s 10-Year Net-margin (%) Range
Min: -53.64   Max: 42.97
Current: -28.68

-53.64
42.97
ROE (%) -91.59
EDAP's ROE (%) is ranked lower than
59% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. EDAP: -91.59 )
EDAP' s 10-Year ROE (%) Range
Min: -142.89   Max: 33.77
Current: -91.59

-142.89
33.77
ROA (%) -24.55
EDAP's ROA (%) is ranked lower than
51% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. EDAP: -24.55 )
EDAP' s 10-Year ROA (%) Range
Min: -35.39   Max: 23.29
Current: -24.55

-35.39
23.29
ROC (Joel Greenblatt) (%) -24.39
EDAP's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. EDAP: -24.39 )
EDAP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -95.07   Max: -4.39
Current: -24.39

-95.07
-4.39
Revenue Growth (%) -14.30
EDAP's Revenue Growth (%) is ranked higher than
50% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. EDAP: -14.30 )
EDAP' s 10-Year Revenue Growth (%) Range
Min: -14.3   Max: 3.5
Current: -14.3

-14.3
3.5
EBITDA Growth (%) -15.90
EDAP's EBITDA Growth (%) is ranked higher than
63% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. EDAP: -15.90 )
EDAP' s 10-Year EBITDA Growth (%) Range
Min: -70.7   Max: 155.4
Current: -15.9

-70.7
155.4
EPS Growth (%) -16.60
EDAP's EPS Growth (%) is ranked higher than
63% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. EDAP: -16.60 )
EDAP' s 10-Year EPS Growth (%) Range
Min: -35.4   Max: 261.7
Current: -16.6

-35.4
261.7
» EDAP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

EDAP Guru Trades in Q1 2013

Robert Bruce 1,565,494 sh (unchged)
» More
Q2 2013

EDAP Guru Trades in Q2 2013

Robert Bruce 1,565,494 sh (unchged)
» More
Q3 2013

EDAP Guru Trades in Q3 2013

Robert Bruce 1,565,494 sh (unchged)
» More
Q4 2013

EDAP Guru Trades in Q4 2013

Robert Bruce 1,565,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1.90
EDAP's P/S is ranked higher than
69% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. EDAP: 1.90 )
EDAP' s 10-Year P/S Range
Min: 0.52   Max: 6.68
Current: 1.9

0.52
6.68
EV-to-EBIT 0.90
EDAP's EV-to-EBIT is ranked higher than
98% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. EDAP: 0.90 )
EDAP' s 10-Year EV-to-EBIT Range
Min: 33.1   Max: 37.2
Current: 0.9

33.1
37.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
EDAP's Price/Median PS Value is ranked higher than
57% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. EDAP: 1.30 )
EDAP' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 4.81
Current: 1.3

0.27
4.81
Earnings Yield (Greenblatt) 116.60
EDAP's Earnings Yield (Greenblatt) is ranked higher than
99% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. EDAP: 116.60 )
EDAP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 124.1
Current: 116.6

2.7
124.1
Forward Rate of Return (Yacktman) -12.44
EDAP's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. EDAP: -12.44 )
EDAP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.4   Max: -17.5
Current: -12.44

-19.4
-17.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EDA.Germany
EDAP TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It believes that the creation of these two divisions has allowed expanding its market share by optimizing worldwide distribution capabilities, all of which is coordinated through its subsidiaries. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2012, the HIFU division's patent portfolio contained 36 patents consisting of 17 in the United States, 17 in the European Union and Japan and 2 in Israel and the rest of the world. They belong to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. As of December 31, 2012, its clinical Ablatherm-HIFU result has been published in 70 renowned peer-reviewed journals. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy.
» More Articles for NAS:EDAP

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide